Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD
Jiraporn Jitprapaikulsan(Mayo Clinic), Sean J. Pittock(Mayo Clinic), Carin Y. Smith(Mayo Clinic in Florida), John E. Schmeling(Centre Hospitalier Universitaire de Martinique), Sarah M. Jenkins(University of Duisburg-Essen), Eoin P. Flanagan, Brian G. Weinshenker(Mayo Clinic in Arizona), Claudia F. Lucchinetti(Mayo Clinic in Arizona), Andrew McKeon(Mayo Clinic), John J. Chen(Mayo Clinic), Jessica Segan(Centre Hospitalier Universitaire de Martinique), John R. Mills(Mayo Clinic), Masoud Majed(Mayo Clinic), James P. Fryer(Mayo Clinic), Yujuan Jiao(Mayo Clinic), Jay Mandrekar(Mayo Clinic in Florida), Philippe Cabre(Centre Hospitalier Universitaire de Martinique), Shannon R. Hinson(Mayo Clinic)
Cited by 65
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k